Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

SMAD2 (mothers against decapentaplegic homolog 2 (Drosophila))

Identity

Other namesMADH2
MADR2
JV18-1
JV18
Hugo SMAD2
Location 18q21.1

DNA/RNA

Description The gene encompasses 90 kb of DNA; 12 exons.
Transcription 2285 nucleotides mRNA. Alternative splicing was described.

Protein

Description 467 amino acids; 52 kDa protein. A short 438 amino acids isoform was also described. Smad2 belongs to the Darfwin proteins family which are composed of two conserved amino- and carboxyl-terminal domains known as MH1 and MH2, respectively.
Expression High expression levels in skeletal muscle, heart and placenta.
Function Smad2 is an intracellular mediator of TGF-beta family and activin type 1 receptor. Smad2 mediate TGF-beta signaling to regulate cell growth and differentiation. Smad2 is released from cytoplasmic retention by TGF-beta receptor-mediated phosphorylation. The phosphorylated Smad2 then forms a heterodimeric complex with Smad4, and this complex translocates from cytoplasm into nucleus. By interacting with DNA-binding proteins, Smad complexes then positively or negatively regulate the transcription of target genes.
Homology With the other members of the Darfwin/Smad family.

Implicated in

Disease Colorectal cancers
Oncogenesis Smad2 was proposed to be a tumor suppressor gene that may function to disrupt TGF-beta signaling. Inactivating mutations in Smad2 have been found in various cancer including colorectal carcinomas. The majority of tumor-derived mutations cluster in the carboxy-terminal MH2 domain, and some of these have been shown to disrupt TGF-beta signaling by blocking receptor-dependent phosphorylation or by preventing heterodimeric interactions between Smads. A mutation at position 133 in the amino-terminal MH1 domain has also been associated with colorectal carcinoma. Nevertheless, loss of Smad2 activation and/or expression was related to occur in less than 10% of colorectal cancers.
  

To be noted

Smad2 gene has also been found alterated in lung carcinomas, cervical carcinomas and hepatocellular carcinomas.

External links

Nomenclature
HugoSMAD2
GDBSMAD2
Entrez_GeneSMAD2  4087  SMAD family member 2
Cards
AtlasSMAD2ID370
GeneCardsSMAD2
EnsemblSMAD2 [Search_View]   ENSG00000175387 [Gene_View]
GenatlasSMAD2
GeneLynxSMAD2
eGenomeSMAD2
euGene4087
Genomic and cartography
GoldenPathSMAD2  -  18q21.1   chr18:43613465-43710924 -  18q21.1   [Description]    (hg18-Mar_2006)
EnsemblSMAD2 - 18q21.1 [CytoView]
NCBIMapview
OMIMDisease map [OMIM]
HomoloGeneSMAD2
Gene and transcription
GenbankAA081871 [ ENTREZ ]
GenbankAA418737 [ ENTREZ ]
GenbankAF027964 [ ENTREZ ]
GenbankAI087928 [ ENTREZ ]
GenbankAI765747 [ ENTREZ ]
RefSeqNM_001003652 [ SRS ]    NM_001003652 [ ENTREZ ]
RefSeqNM_005901 [ SRS ]    NM_005901 [ ENTREZ ]
RefSeqAC_000061 [ SRS ]    AC_000061 [ ENTREZ ]
RefSeqNC_000018 [ SRS ]    NC_000018 [ ENTREZ ]
RefSeqNT_010966 [ SRS ]    NT_010966 [ ENTREZ ]
RefSeqNW_927106 [ SRS ]    NW_927106 [ ENTREZ ]
AceViewSMAD2 AceView - NCBI
UnigeneHs.705764 [ SRS ]    Hs.705764 [ NCBI ]     HS705764 [ spliceNest ]
Fast-db4185 (alternative variants)
Protein : pattern, domain, 3D structure
SwissProtQ15796 [ SRS]    Q15796 [ EXPASY ]     Q15796 [ INTERPRO ]
PrositePS51075 MH1 [ SRS ]    PS51075 MH1 [ Expasy ]
PrositePS51076 MH2 [ SRS ]    PS51076 MH2 [ Expasy ]
InterproIPR013790 Dwarfin [ SRS ]    IPR013790 Dwarfin [ EBI ]
InterproIPR013019 MAD_MH1 [ SRS ]    IPR013019 MAD_MH1 [ EBI ]
InterproIPR003619 MH1_Dwarfin-type [ SRS ]    IPR003619 MH1_Dwarfin-type [ EBI ]
InterproIPR001132 MH2_Dwarfin-type [ SRS ]    IPR001132 MH2_Dwarfin-type [ EBI ]
CluSTrQ15796
PfamPF03165 MH1 [ SRS ]    PF03165 MH1 [ Sanger ]    pfam03165 [ NCBI-CDD ]
PfamPF03166 MH2 [ SRS ]    PF03166 MH2 [ Sanger ]    pfam03166 [ NCBI-CDD ]
SmartSM00523 DWA [EMBL]
SmartSM00524 DWB [EMBL]
BlocksQ15796
PDB1DEV [ SRS ]    1DEV [ PdbSum ],   1DEV [ IMB ]   1DEV [ RSDB ]
PDB1KHX [ SRS ]    1KHX [ PdbSum ],   1KHX [ IMB ]   1KHX [ RSDB ]
PDB1U7V [ SRS ]    1U7V [ PdbSum ],   1U7V [ IMB ]   1U7V [ RSDB ]
HPRD03221
Protein Interaction databases
DIPQ15796
IntActQ15796
Polymorphism : SNP, mutations, diseases
OMIM601366    [ map ]   
GENECLINICS601366
SNPSMAD2 [dbSNP-NCBI]  
SNPNM_001003652 [SNP-NCI]  
SNPNM_005901 [SNP-NCI]  
SNPSMAD2 [GeneSNPs - Utah]  SMAD2] [HGBASE - SRS]
HAPMAPSMAD2 [HAPMAP]  
COSMICSMAD2 [Somatic mutation (COSMIC-CGP-Sanger)]  
HGMDSMAD2
General knowledge
Family BrowserSMAD2 [UCSC Family Browser]
SOURCENM_001003652
SOURCENM_005901
SMDHs.705764
SAGEHs.705764
GOmesoderm formation [Amigo]  mesoderm formation
GOdouble-stranded DNA binding [Amigo]  double-stranded DNA binding
GOtranscription factor activity [Amigo]  transcription factor activity
GOintracellular [Amigo]  intracellular
GOnucleus [Amigo]  nucleus
GOtranscription factor complex [Amigo]  transcription factor complex
GOcytoplasm [Amigo]  cytoplasm
GOtranscription [Amigo]  transcription
GOintracellular signaling cascade [Amigo]  intracellular signaling cascade
GOtranscription factor binding [Amigo]  transcription factor binding
GOtranscription factor binding [Amigo]  transcription factor binding
GOanterior/posterior pattern formation [Amigo]  anterior/posterior pattern formation
GOtranscription activator activity [Amigo]  transcription activator activity
GOregulation of transforming growth factor beta receptor signaling pathway [Amigo]  regulation of transforming growth factor beta receptor signaling pathway
GOcell fate commitment [Amigo]  cell fate commitment
GOnegative regulation of transcription, DNA-dependent [Amigo]  negative regulation of transcription, DNA-dependent
GOpositive regulation of transcription from RNA polymerase II promoter [Amigo]  positive regulation of transcription from RNA polymerase II promoter
GOparaxial mesoderm morphogenesis [Amigo]  paraxial mesoderm morphogenesis
GOregulation of binding [Amigo]  regulation of binding
BIOCARTATGF beta signaling pathway    [Genes]
KEGGCell cycle
KEGGWnt signaling pathway
KEGGTGF-beta signaling pathway
KEGGAdherens junction
KEGGColorectal cancer
PubGeneSMAD2
TreeFamSMAD2
CTD4087 [Comparative ToxicoGenomics Database]
Other databases
Probes
ProbeSMAD2 Related clones (RZPD - Berlin)
PubMed
PubMed161 Pubmed reference(s) in LocusLink

Bibliography

A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway.
Baker JC, Harland RM
Genes & development. 1996 ; 10 (15) : 1880-1889.
PMID 8756346
 
MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma.
Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L
Cell. 1996 ; 86 (4) : 543-552.
PMID 8752209
 
MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling.
Macˆ‚as-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL
Cell. 1996 ; 87 (7) : 1215-1224.
PMID 8980228
 
Mad-related genes in the human.
Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, Hamilton SR, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B
Nature genetics. 1996 ; 13 (3) : 347-349.
PMID 8673135
 
Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers.
Uchida K, Nagatake M, Osada H, Yatabe Y, Kondo M, Mitsudomi T, Masuda A, Takahashi T, Takahashi T
Cancer research. 1996 ; 56 (24) : 5583-5585.
PMID 8971158
 
Identification of Smad2, a human Mad-related protein in the transforming growth factor beta signaling pathway.
Nakao A, Rˆijer E, Imamura T, Souchelnytskyi S, Stenman G, Heldin CH, ten Dijke P
The Journal of biological chemistry. 1997 ; 272 (5) : 2896-2900.
PMID 9006934
 
Somatic alterations of the SMAD-2 gene in human colorectal cancers.
Takagi Y, Koumura H, Futamura M, Aoki S, Ymaguchi K, Kida H, Tanemura H, Shimokawa K, Saji S
British journal of cancer. 1998 ; 78 (9) : 1152-1155.
PMID 9820171
 
Characterization of the MADH2/Smad2 gene, a human Mad homolog responsible for the transforming growth factor-beta and activin signal transduction pathway.
Takenoshita S, Mogi A, Nagashima M, Yang K, Yagi K, Hanyu A, Nagamachi Y, Miyazono K, Hagiwara K
Genomics. 1998 ; 48 (1) : 1-11.
PMID 9503010
 
Mutation analysis of the Smad2 gene in human colon cancers using genomic DNA and intron primers.
Takenoshita S, Tani M, Mogi A, Nagashima M, Nagamachi Y, Bennett WP, Hagiwara K, Harris CC, Yokota J
Carcinogenesis. 1998 ; 19 (5) : 803-807.
PMID 9635866
 
Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo.
Waldrip WR, Bikoff EK, Hoodless PA, Wrana JL, Robertson EJ
Cell. 1998 ; 92 (6) : 797-808.
PMID 9529255
 
Evidence that Smad2 is a tumor suppressor implicated in the control of cellular invasion.
Prunier C, Mazars A, Noˆ“ V, Bruyneel E, Mareel M, Gespach C, Atfi A
The Journal of biological chemistry. 1999 ; 274 (33) : 22919-22922.
PMID 10438456
 
Smad2 and Smad4 gene mutations in hepatocellular carcinoma.
Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M
Oncogene. 1999 ; 18 (34) : 4879-4883.
PMID 10490821
 
Identification and characterization of constitutively active Smad2 mutants: evaluation of formation of Smad complex and subcellular distribution.
Funaba M, Mathews LS
Molecular endocrinology (Baltimore, Md.). 2000 ; 14 (10) : 1583-1591.
PMID 11043574
 
Mutation analysis of SMAD2, SMAD3, and SMAD4 genes in hereditary non-polyposis colorectal.
Roth S, Johansson M, Loukola A, Peltomˆ§ki P, Jˆ§rvinen H, Mecklin JP, Aaltonen LA
Journal of medical genetics. 2000 ; 37 (4) : 298-300.
PMID 10819637
 
Structural basis of Smad2 recognition by the Smad anchor for receptor activation.
Wu G, Chen YG, Ozdamar B, Gyuricza CA, Chong PA, Wrana JL, Massaguˆ© J, Shi Y
Science (New York, N.Y.). 2000 ; 287 (5450) : 92-97.
PMID 10615055
 
Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway.
Xu J, Attisano L
Proceedings of the National Academy of Sciences of the United States of America. 2000 ; 97 (9) : 4820-4825.
PMID 10781087
 
Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling.
Wu JW, Hu M, Chai J, Seoane J, Huse M, Li C, Rigotti DJ, Kyin S, Muir TW, Fairman R, Massaguˆ© J, Shi Y
Molecular cell. 2001 ; 8 (6) : 1277-1289.
PMID 11779503
 
Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFbeta signaling complexes in the cytoplasm and nucleus.
Xu L, Kang Y, Cˆl S, Massaguˆ© J
Molecular cell. 2002 ; 10 (2) : 271-282.
PMID 12191473
 
Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer.
Maliekal TT, Antony ML, Nair A, Paulmurugan R, Karunagaran D
Oncogene. 2003 ; 22 (31) : 4889-4897.
PMID 12894231
 
Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis.
Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M
Cancer journal (Sudbury, Mass.). 2003 ; 9 (4) : 302-312.
PMID 12967141
 
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

Contributor(s)

Written07-2004Raphael Saffroy, Antoinette Lemoine, Brigitte Debuire

Citation

This paper should be referenced as such :
Saffroy R, Lemoine A, Debuire B . SMAD2 (mothers against decapentaplegic homolog 2 (Drosophila)). Atlas Genet Cytogenet Oncol Haematol. July 2004 .
URL : http://AtlasGeneticsOncology.org/Genes/SMAD2ID370.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Jul 2 08:27:05 2008


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

j.l.huret@chu-poitiers.fr.